MedPath
FDA Approval

TERBINAFINE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Chartwell RX, LLC
DUNS: 079394054
Effective Date
October 6, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Terbinafine(250 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Chartwell Pharmaceuticals Congers, LLC

Chartwell RX, LLC

Chartwell Pharmaceuticals Congers, LLC

118673447

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TERBINAFINE

Product Details

NDC Product Code
62135-572
Application Number
ANDA078199
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
October 6, 2023
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
METHYLCELLULOSE, UNSPECIFIEDInactive
Code: Z944H5SN0HClass: IACT
Code: 012C11ZU6GClass: ACTIMQuantity: 250 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath